

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/3/2008; page 1 TMP 045

Guggested Formula Aminophylline 25 mg/mL Intramuscular Injection (Solution, 100 mL)	FIN	F 000 740V2	
---	-----	-------------	--

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Aminophylline, USP	2.500	g				
Sterile Water For Injection, USP	90.0	mL				
Sterile Water For Injection, USP	q.s. to 100.0	mL				
Ethylenediamine 10% Solution †	As required		(6)	1		
)		
† Ethylenediamine 10% Solution						
Ethylenediamine, USP	5.0	mL				
Sterile Water For Injection, USP	45.0	mL	401	>		

SPECIAL PREPARATORY CONSIDERATIONS

ECIAL PREPARATORY CONSI	IDERATIONS
Ingredient-Specific Information	
Light sensitive (protect from li	ight whenever possible): Aminophylline
Suggested Preparatory Guidelines	
Non-Sterile Preparat	tion Sterile Preparation
Processing Error / Testing Considerations:	To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP</i> 797. Only trained and qualified personnel must prepare this formula.
	All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.
	Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.
	Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.
	Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/3/2008; page 2 TMP 045

Suggested Formula

Aminophylline 25 mg/mL Intramuscular Injection (Solution, 100 mL)

FIN

F 000 740V2

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Aminophylline, USP §	2.500	g			
Sterile Water For Injection, USP §	90.0	mL			
Sterile Water For Injection, USP §	q.s. to 100.0	mL	®		
Ethylenediamine 10% Solution § †	As required				
† Ethylenediamine 10% Solution		P			
Ethylenediamine, USP §	5.0	mL			
Sterile Water For Injection, USP §	45.0	mL			

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

	Preparatory Instruction
	IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique
1.	Equipment sterilization:
	Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
2.	Ethylenediamine 10% Solution preparation:
	A. Combine and mix the following ingredients together until homogeneously dispersed:
	- Ethylenediamine (5.0 mL)
	- Sterile Water For Injection (45.0 mL)
	End result: Homogeneous liquid-like solution.
3.	Powder to liquid integration:
	A. Incrementally add the following ingredient to the Sterile Water For Injection (90.0 mL plus processing error adjustments):
	- Aminophylline
	Specifications: Continuously mix until all solid particles have completely dissolved.
	End result: Homogeneous liquid-like solution.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/3/2008; page 3

Suggested Formula	Aminophylline 25 mg/mL Intramuscular Injection (Solution, 100 mL)	FIN	F 000 740V2
----------------------	---	-----	-------------

4. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 3A).
- B. Test the pH of the sample. It should lie between 8.6 and 9.0.
- C. If the pH < 8.6, carefully add in a dropwise manner the Ethylenediamine 10% Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Ethylenediamine 10% Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Ethylenediamine 10% Solution.
 - Re-test the pH.
 - 4. Continue to add the Ethylenediamine 10% Solution until the pH of 8.6 to 9.0 is obtained.

IMPORTANT: Do not allow the pH to rise above 9.0.

5. **Filling to volume:**

A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specifications: Continuously mix.

End result: Homogeneous liquid-like solution.

6. Filtering and transferring:

- A. Aseptically filter the solution through a 0.22-μm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.
- B. Flush the remaining airspace of the vial with Nitrogen gas before sealing. This will reduce exposure to air, thus preventing turbidity and crystal formation.

7. **Filter integrity test:**

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

8. **Sterility testing:**

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.



TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/3/2008; page 4 TMP 045

Suggested Formula	Aminophylline 25 mg/mL Intramuscular Injection (Solution, 100 mL)	FIN	F 000 740V2
----------------------	---	-----	-------------

SUGGESTED PRESENTATION

COLUTED I KI		TITALION .			
Estimated Beyond-Use Date		14 days BUD based on a successful sterility and endotoxin test result.	Requiremen		Sterile, light-resistant, unit dose injection vials.
	1	Use as directed. Do not exceed dose.	l prescribed	5	Protect from light.
	2	Keep out of reach of children.		6	Discard container after use.
Auxiliary Labels	3	Discard in the presence of matter.	particulate	7	Keep at room temperature (20 – 23°C).
4 Do not use if discolored. 8 prescription or over are currently being		Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.			
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.					
Patient Instructions	Co	ntact your pharmacist in the event	of adverse re	actio	ons.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/3/2008; page 5

Suggested Formula	Aminophylline 25 mg/mL Intramuscular Injection (Solution, 100 mL)	FIN	F 000 740V2	
----------------------	---	-----	-------------	--

REFERENCES

1.	Buffered and Isotonic Solutions. In: Martin A. <i>Physical Pharmacy, Fourth Edition</i> . Philadelphia, PA: Lipponcott Williams & Wilkins; 1993:169-89.
2.	Aminophylline. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 34 th Edition. London, England: The Pharmaceutical Press; 2005: 280.
3.	Aminophylline (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 81.
4.	Ethylenediamine (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 675.
5.	Aminophylline (Monograph). US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc. 2001: 15.
6.	<797> Pharmacy Compounding. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20.</i> Rockville, MD: US Pharmacopeial Convention, Inc, 2001: 2053.
7.	Aminophylline. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 2 nd Edition. American Pharmaceutical Association; 2000: 118.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.